{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"This is to measure the effect of Pasireotide LAR (long-acting release) treatment.","groups":[{"description":"Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed.\n\nPasireotide LAR: Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.\n\nThe starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.","id":"OG000","title":"Pasireotide LAR Therapy"}],"populationDescription":"The study was terminated due to poor enrollment. The data was not collected or analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline, 12 months","title":"Change in Plasma Proopiomelanocortin (POMC) Levels","type":"PRIMARY"}